Marinus Pharmaceuticals, Inc
MRNS
MRNS was delisted on the 10th of February, 2025.
87 hedge funds and large institutions have $480M invested in Marinus Pharmaceuticals, Inc in 2021 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 44 increasing their positions, 18 reducing their positions, and 12 closing their positions.
144% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 18
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
27% more capital invested
Capital invested by funds: $378M → $480M (+$103M)
8% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 12
1% less funds holding
Funds holding: 88 → 87 (-1)
66% less call options, than puts
Call options by funds: $3.65M | Put options by funds: $10.8M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$9.35M |
| 2 |
AG
Artal Group
Luxembourg
|
+$7.23M |
| 3 |
SCM
Suvretta Capital Management
New York
|
+$5.73M |
| 4 |
SAM
Scion Asset Management
Saratoga,
California
|
+$4.3M |
| 5 |
Goldman Sachs
New York
|
+$2.42M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$15.9M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$8.9M |
| 3 |
LM
Luminus Management
Houston,
Texas
|
-$4.33M |
| 4 |
KPWS
Kestra Private Wealth Services
Austin,
Texas
|
-$2.47M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$1.95M |
MRNS Hedge Fund Activity: Q1 2021 in Review
87 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Marinus Pharmaceuticals, Inc (MRNS) for Q1 2021, worth a combined $480M — up 27% from $378M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of MRNS and 11 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 44 added.
The largest buyer was BlackRock, adding an estimated $9.35M. The largest seller was RA Capital Management, exiting entirely with an estimated $15.9M sold.
- 87 institutional investors held Marinus Pharmaceuticals, Inc (MRNS) as of Q1 2021, down from 88 in Q4 2020.
- Funds reported $480M of Marinus Pharmaceuticals, Inc stock for Q1 2021, up 27% quarter-over-quarter.
- 11 funds opened new Marinus Pharmaceuticals, Inc positions in Q1 2021 and 12 closed out, a net change of -1 holder.
- The largest Marinus Pharmaceuticals, Inc buyer in Q1 2021 was BlackRock, an estimated $9.35M added.
- The largest Marinus Pharmaceuticals, Inc seller in Q1 2021 was RA Capital Management, an estimated $15.9M sold.
Based on aggregated 13F filings for Q1 2021.